Qvir Kit

Qvir KIT is indicated for the treatment of HIV-1 infection in adults and adolescents weighing at least 40 kg and aged12 years and above.

The following points should be considered when initiating therapy with Qvir KIT:

•        In Study AI424-045, atazanavir/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. This study was not large enough to reach a definitive conclusion that atazanavir/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection.
•        The number of baseline primary protease inhibitor mutations affects the virological response to atazanavir/ritonavir.
•        It is not recommended that emtricitabine/tenofovir DF be used as a component of a triple nucleoside regimen.
•        Emtricitabine/tenofovir DF should not be coadministered with emtricitabine/tenofovir DF/efavirenz, emtricitabine, tenofovir DF or lamivudine-containing products (see WARNINGS AND PRECAUTIONS).
•        In treatment experienced patients, the use of emtricitabine/tenofovir DF should be guided by laboratory testing and treatment history.